UPDATE 1-Moderna says US FDA refuses to review its influenza vaccine

Moderna +1.74%

Moderna

MRNA

53.76

+1.74%

Adds details in paragraph 2-3

Feb 10 (Reuters) - Moderna MRNA.O said on Tuesday the U.S. Food and Drug Administration will not review its approval application for its influenza vaccine.

The company said it had exercised a priority review voucher to fast track its application.

Moderna said it has requested a meeting with the regulator to understand the path forward.



This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.